Skye Bioscience, Inc. (SKYE)

USD 3.01

(-7.38%)

Market Cap (In USD)

91.31 Million

Revenue (In USD)

-

Net Income (In USD)

-37.64 Million

Avg. Volume

337.24 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.25-19.41
PE
-
EPS
-
Beta Value
1.75
ISIN
US83086J2006
CUSIP
83086J101
CIK
1516551
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Punit S. Dhillon B.A.
Employee Count
-
Website
https://skyebioscience.com
Ipo Date
2014-11-26
Details
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.